Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats.

OBJECTIVE: This study intended to explore the hypoglycemic and cardioprotective effects of 8-week aerobic interval training combined with liraglutide and elucidate the underlying mechanisms. METHOD: Male Wistar rats were randomly divided into 5 groups - normal control group (CON), diabetic cardiomyopathy group (DCM), high-dose liraglutide group (DH), low-dose liraglutide group (DL), and aerobic interval training combined with liraglutide group (DLE). High-fat diet and streptozotocin (STZ) were used to induce the DCM model, and both the liraglutide administration group and combination therapy group allocated to 8 weeks of either liraglutide or liraglutide and exercise intervention. Cardiac functions were analyzed by electrocardiography. Blood biochemical parameters were measured to judge glycemic control conditions. Hematoxylin and eosin (HE) staining and Sirus red staining was used to identify cardiac morphology and collagen accumulation, respectively. Advanced glycation end products (AGEs) were determined by enzymatic methods. The mRNA expression of myocardial remodeling genes (BNP, GSK3ß, α-MHC, ß-MHC and PPARα) and the protein expression of GLP-1, GLP-1R were analyzed. RESULTS: DCM rats developed hyperglycemia, impaired cardiac function with accumulation of AGEs and collagen (P < 0.05). The development of hyperglycemia and cardiac dysfunction was significantly attenuated with all interventions, as reduced cardiac fibrosis and improved cardiac function (P < 0.05). Cardiac remodeling genes were normalized after all interventions, these positive modifications were due to increased GLP-1 and GLP-1R expression in DCM heart (P < 0.05). Liraglutide combined with AIT significantly increased the diameters of cardiomyocytes, increased the α-MHC expressionx, reduced PPARαexpression and reduced the fluctuation of blood glucose level, which showed the safety and effective of medicine combined with exercise. CONCLUSION: Liraglutide combined with AIT intervention normalized blood glucose alleviates myocardial fibrosis and improves cardiac contractile function in DCM rats, supporting the efficacy and safety of the combination therapy.

The Relationship Between Triglyceride Glucose Index and Vitamin D in Type 2 Diabetes Mellitus.

PURPOSE: The study aimed to investigate the relationship between 25-hydroxyvitamin D [25(OH) D] and triglyceride glucose index (TyG) levels in male and female patients with type 2 diabetes mellitus (T2DM). PATIENTS AND METHODS: This cross-sectional study recruited 592 patients with type 2 diabetes. The subjects were divided into the non-vitamin D deficiency group [25(OH)D≥20ng/mL] and the vitamin D deficiency group [25(OH)D<20ng/mL]. The triglyceride glucose (TyG) index is calculated using the following formula, ln[fasting triglycerides (mg/dL)*fasting blood glucose (mg/dL)/2]. Participants were divided into high TyG group and low TyG group, with the median of TyG as the boundary. All participants were divided into male and female groups and normal Body mass index (BMI) and high BMI groups, and then divided into high TyG group and low TyG group. RESULTS: We found that TyG levels are independently and negatively correlated with vitamin D levels in male patients with T2DM. In the female group, there was no significant correlation between TyG and vitamin D levels, regardless of an adjusted or unadjusted confounding factor. Subgroup analysis showed that the correlation between TyG and the risk of vitamin D deficiency in the normal BMI group was significantly stronger than that in the high BMI group. CONCLUSION: This study indicates that vitamin D deficiency is related to high TyG level in patients with T2DM for males, and this relationship is not significant for female patients. The risk of vitamin D deficiency is significantly correlated with high TyG level in normal BMI group. However, there was no statistically significant difference between TyG level and the risk of vitamin D deficiency in the high BMI group. Difference between TyG level and the risk of vitamin D deficiency.